扩张型心肌病患者两种治疗方法前后microRNA-126和microRNA-30a水平表达的研究  

Study on the Expression of MicroRNA-126 and Microrna-30a in Patients with Dilated Cardiomyopathy before and after Two Treatments

作　　者：周红 娜日罕 荣钰 董莉[1] ZHOU Hong;NA Ri-han;RONG Yu;DONG Li(Department of Clinical Laboratory,the Affiliated Hospital of Inner Mongolia Medical University,Hohehot 010050,China)

机构地区：[1]内蒙古医科大学附属医院检验科,呼和浩特010050

出　　处：《现代检验医学杂志》2020年第4期6-9,共4页Journal of Modern Laboratory Medicine

基　　金：内蒙古自治区自然基金(2017MS0826);内蒙古科技计划基金(NMKJZD20170742)。

摘　　要：目的探讨microRNA-126(miRNA-126)和microRNA-30a(miRNA-30a)检测在扩张型心肌病(dilated cardiomyopathy,DCM)患者诊断及预后评估的价值。方法收集2014.2~2019.3期间40例DCM患者,按治疗方法分为手术治疗组20例和一般治疗组20例,同期健康体检者20例为对照组,采用qRT-PCR法检测治疗前后患者血清中miRNA-126和miRNA-30a的相对含量,并进行统计学分析。结果①DCM患者与对照组血清miRNA-126相对表达量为[1.40(0.44,3.28)vs 1.15(0.44,2.25)],miRNA-30a为[2.37(0.70,4.25)vs 1.05(0.48,2.20)],差异无统计学意义(Z=-0.557,-1.662,P>0.05)。②治疗后,一般治疗组miRNA-126为1.35(0.66,2.00),miRNA-30a为1.2(0.77,4.55)。手术治疗组miRNA-126为0.16(0.10,0.26),miRNA-30a为0.20(0.14,0.33),手术治疗组治疗前后miRNA-126,miRNA-30a表达量差异有统计学意义(均Z=-3.059,均P<0.05)。一般治疗及手术治疗两者表达量差异有统计学意义(miRNA-126:Z=-3.806,P<0.05;miRNA-30a:Z=-3.24,P<0.05)。③miRNA-126与NT-proBNP呈负相关;循环miRNA-30a与NT-proBNP呈正相关,与射血分数呈负相关。④miRNA-126的12个月相对危险度为0.768(95%CI 0.431~1.37,P>0.05),miRNA-30a的12个月生存分析其相对危险度为1.141(95%CI 0.775~1.678,P>0.05)。结论miRNA-126和miRNA-30a可为两种不同治疗方法的评价提供一定的参考价值。Objective To investigate the value of microRNA-126(mirna-126)and microRNA-30a(miRNA-30a)in the diagnosis and prognosis of patients with dilated cardiomyopathy(DCM).Methods 40 patients with DCM from February 2014 to March 2019 were collected.According to the treatment methods,20 patients were divided into operation treatment group,20 general treatment group and 20 healthy people in the same period as the control group.The relative contents of miRNA-126 and miRNA-30a in the serum of patients before and after treatment were detected by qRT-PCR,and the statistical analysis was carried out.Results①the relative expression of miRNA-126 was[1.40(0.44,3.28)vs 1.15(0.44,2.25)]and miRNA-30a was[2.37(0.70,4.25)vs 1.05(0.48,2.20)],the difference was not statistically significant(Z=-0.557,-1.662,P>0.05).②After treatment,miRNA-126 and mirna-30a in general treatment group were 1.35(0.66,2.00)and 1.2(0.77,4.55)respectively.MiRNA-126 and miRNA-30a in the operation group were 0.16(0.10,0.26)and 0.20(0.14,0.33),respectively.The expression of miRNA-126 and miRNA-30a in the operation group was significantly different before and after treatment(all Z=-3.059,P<0.05).The difference of expression between general treatment and operation treatment was statistically significant(miRNA-126:Z=-3.806,P<0.05;miRNA-30a:Z=-3.24,P<0.05).③MiRNA-126 was negatively correlated with NT proBNP,circulating miRNA-30a was positively correlated with NT proBNP and negatively correlated with ejection fraction.④The 12-month relative risk of miRNA-126 was 0.768(95%CI 0.431~1.37,P>0.05),and the 12-month survival analysis of miRNA-30a was 1.141(95%CI 0.775~1.678,P>0.05).Conclusion miRNA-126 and miRNA-30a can provide some reference value for the evaluation of two different treatment methods.

关 键 词：扩张型心肌病 微小核糖核酸-126 微小核糖核酸-30a 

分 类 号：R542.2[医药卫生—心血管疾病] R392.11[医药卫生—内科学]